Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
February 18, 2008
- Kyushu Medical Association Decides to Support Dr Karasawa
February 18, 2008
- Herceptin Approved for Postoperative Adjuvant Chemotherapy
February 18, 2008
- Takeda to Use Amgen Japanas Development Subsidiary
February 18, 2008
- No Problems Found in EPPV of Velcade, Alimta
February 18, 2008
- Objection to Use of Literature by MRs without Obtaining Prior Consent
February 18, 2008
- REGULATORY NEWS IN BRIEF
February 18, 2008
- Takeda Begins PIII for Combination of Actos and DPP-4 Inhibitor
February 18, 2008
- Successor of Prograf Will Not Reach US Market before Expiration of Its Patent
February 18, 2008
- TMDU, Nippon Chemiphar Report Efficacy of NC-2300 for Autoimmune Disease
February 18, 2008
- CDK Inhibitors Are Also Effective for RA
February 18, 2008
- R&D NEWS IN BRIEF
February 18, 2008
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 18, 2008
- Taiyo Completes Expansion of Its Production Facilities
February 18, 2008
- Aricept, Pariet/AcipHex Drive Eisai's Business
February 18, 2008
- Towa to Establish Overnight Delivery System via Network of Hansha
February 18, 2008
- Nobelpharma to Launch 3 New Drugs
February 18, 2008
- Survey／COPD Awareness Rate Remains Unchanged at 34%: NBI/Pfizer Survey
February 18, 2008
- Takara Bio to Launch World's First Protein Regulation System
February 18, 2008
- GENERICS NEWS IN BRIEF
February 18, 2008
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…